selumetinib

An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
0204020082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
BACKGROUND Effective medical therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
IMPORTANCE Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis. In… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND No targeted therapies are available for KRAS-mutant non-small-cell lung cancer (NSCLC). Selumetinib is an inhibitor of… (More)
  • figure 1
  • table 2
  • table 1
  • table 4
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could be targeted to… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK… (More)
  • table 1
  • table 3
  • table 4
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined cancers. Although most patients… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Background:The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a number of inhibitors that target this pathway… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase kinase (MEK… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Selumetinib (AZD6244, ARRY-142886) is a selective, non-ATP-competitive inhibitor of mitogen-activated protein/extracellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?